Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
Philip J MeaseMark C GenoveseMichael E WeinblattPaul M PelosoKun ChenAhmed A OthmanYihan LiHeikki T MansikkaAmit KhatriNeil WishartJohn LiuPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.
Keyphrases
- smoking cessation
- phase ii study
- rheumatoid arthritis
- prostate cancer
- open label
- locally advanced
- high dose
- squamous cell carcinoma
- cancer therapy
- juvenile idiopathic arthritis
- randomized controlled trial
- clinical trial
- radiation therapy
- rectal cancer
- radical prostatectomy
- systemic lupus erythematosus
- ulcerative colitis